About Us
Built on Science,
Driven by Transparency
FitSupp Analytics was created because we believed athletes and fitness enthusiasts deserve unbiased, evidence-based information—not marketing copy dressed up as science.
Our Mission
Cutting Through the Supplement Industry Noise
The sports supplement industry is worth over $50 billion globally—and much of that value is built on exaggerated claims, underdosed products, and proprietary blends designed to obscure rather than inform.
We started FitSupp Analytics to create a resource that exists purely in service of accurate information. Our editorial decisions are never influenced by commercial relationships, advertising revenue, or brand partnerships.
Our Principles
What We Stand For
These aren't aspirational marketing statements—they're operational constraints built into how we work every day.
Every claim is backed by peer-reviewed literature. We clearly distinguish between established facts, emerging evidence, and speculation. We update our content when new research changes the picture.
We disclose our methodology, cite our sources, and acknowledge limitations in the evidence. We have zero financial relationships with supplement manufacturers or distributors.
All information on FitSupp Analytics is permanently free. No subscriptions, no paywalls, no "premium" tiers. We believe access to accurate health information is a right, not a privilege.
We don't reflexively dismiss supplements or hype them. Each ingredient gets an honest appraisal of where the evidence is strong, where it's weak, and what remains unknown.
Nutritional science evolves. We continuously review and revise our analyses as new research is published, ensuring our platform reflects the current state of the literature.
Our readers drive our research agenda. We welcome questions, corrections, and feedback—and we use them to improve the depth and accuracy of our content.
The Team
Who's Behind FitSupp Analytics
Our editorial team combines academic research backgrounds with practical experience in sports nutrition and performance coaching.
PhD in Exercise Physiology. 12 years researching ergogenic aids at university level before founding FitSupp Analytics.
Registered Dietitian specializing in sports nutrition. Former consultant to Olympic-level athletes. Oversees all macronutrient and micronutrient content.
MSc Biochemistry. Specializes in metabolic pathways, bioavailability research, and pharmacokinetics of nutritional compounds.
MD with a focus on sports medicine. Leads our adverse event review process and drug-supplement interaction database.
Research Process
How We Conduct Our Research
Our review process follows a structured, reproducible methodology designed to minimize bias and ensure comprehensive coverage of the available literature.
Important Disclaimer: All information on FitSupp Analytics is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before beginning any supplementation regimen.
We search PubMed, Cochrane Library, SPORTDiscus, and CINAHL using standardized search strings for each ingredient. We cast wide nets initially and then apply inclusion/exclusion criteria. We prioritize randomized controlled trials, systematic reviews, and meta-analyses. We do not restrict searches by publication date but weight recent high-quality studies more heavily.
Each study is assessed using standardized quality checklists (e.g., Jadad scale for RCTs, AMSTAR for meta-analyses). We evaluate sample size, blinding quality, placebo design, funding source transparency, and statistical rigor. Studies with significant conflicts of interest receive additional scrutiny.
We apply a simplified evidence grade (A through D) to each ingredient's primary claimed benefits. Grade A indicates consistent findings from multiple well-designed RCTs or meta-analyses. Grade D indicates evidence limited to animal studies, mechanistic data only, or conflicting low-quality human trials.
Safety assessments incorporate GRAS (Generally Recognized as Safe) status, FDA adverse event reporting data, published case reports of adverse events, known drug-supplement interactions, and population-specific considerations (e.g., contraindications during pregnancy). Safety ratings are updated when new adverse event data emerges.
All completed analyses are reviewed by at least two team members with relevant expertise before publication. Significant disagreements are resolved through discussion or consultation with external advisors. Publication includes a "Last Reviewed" date and a changelog for major updates.